Weekly Roundup: June 1-5

Jun 05, 2020, 10:55am

In case you missed it, this week we featured stories involving blastic plasmacytoid dendritic cell neoplasm (BPDCN), development of a biosimilar to BOTOX, a new nonmelanoma treatment device, the latest phase 3 results for abrocitinib in atopic dermatitis, results from a long-term dabrafenib and trametinib study in stage 3 BRAF-mutated melanoma, plus many more.

In case you missed it, this week we featured stories involving blastic plasmacytoid dendritic cell neoplasm (BPDCN), development of a biosimilar to BOTOX, a new nonmelanoma treatment device, the latest phase 3 results for abrocitinib in atopic dermatitis, results from a long-term dabrafenib and trametinib study in stage 3 BRAF-mutated melanoma, plus many more.

Genetic features pave way for targeted BPDCN therapies
Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. With one approved treatment and several in clinical trials, there are promising and much needed therapeutic options coming.

ASLMS gains new president and officers
The American Society for Laser Medicine and Surgery announces a new president and officers will be joining their Board of Directors for 2020-21.

Systemic antibiotics impact skin microbiota in rosacea patients
A recent study published in the Journal of Clinical Medicine evaluated the changes seen in the skin’s microbiota of patients following antibiotic therapy to elucidate which organisms might play the biggest role in development of rosacea symptoms.

Revance, Mylan to collaborate on biosimilar to BOTOX
Mylan has agreed to move forward with Revance in the development plan of a biosimilar to onabotulinumtoxinA (BOTOX, AbbVie) under the 351(k) regulatory pathway from the U.S. FDA.

BPDCN patient at increased risk of second primary malignancies
Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

AbbVie seeks approval for upadacitinib in U.S., Europe for psoriatic arthritis
AbbVie announces they have filed applications with the U.S. FDA and EMA for the approval of the JAK inhibitor upadacitinib for the treatment of adult active psoriatic arthritis.

New device treats nonmelanoma skin cancer
A new energy-based device delivering ultrafast pulses of high amplitude electrical energy to nonthermally preferentially clear targeted cell rich lesions is proving to be a very useful treatment modality for a number of benign dermatologic lesions.

Thayers launches acne-tailored skincare line
In honor of June being Acne Awareness Month, Thayers has launched a new line of acne-tailored skincare products.

5-year follow-up demonstrates long-term benefit of dabrafenib/trametinib for stage 3 melanoma
Results presented at the recent ASCO 2020 Virtual Scientific Program demonstrate the long-term relapse-free and survival benefit of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) as a combination treatment following surgery in stage III BRAF V600E/K-mutant melanoma patients.

Pfizer reports positive results from second abrocitinib monotherapy study
Full results from the second of two trials investigating the JAK1 inhibitor abrocitinib as a monotherapy for treatment of moderate-to-severe atopic dermatitis demonstrate statistical superiority of both doses compared to placebo.

Melanoma tumor syndromes
Recognition of patients with hereditary melanoma is important not only because these individuals require careful surveillance for future primary melanomas, but also because they may be predisposed to multiple other types of malignancies because of their genetic mutation, says Hensin Tsao, M.D., Ph.D.

Research gains traction for hidradenitis suppurativa
Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.